Press Releases

Record-breaking holiday gift drive responds to increased homelessness rates

Praluent® is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies, including OptumRx and UnitedHealthcare Commercial, Medicare, and Managed Medicaid formularies

New 24 and 32-Packs Designed to Manage Dosage Regimens for both Latent and Active Tuberculosis

- A study conducted with 1,500 Americans in July 2015 examined perceived risks of counterfeit medicines[1] -

- 74 percent of patients reached their LDL cholesterol goals on 75 mg dose; Of the remaining patients whose dose was adjusted to 150 mg, most achieved their goal -

- Data Show Significant Improvement in Signs and Symptoms and Physical Function in Rheumatoid Arthritis Patients who were Inadequate Responders to or Intolerant of TNF-Alpha Inhibitors (TNF-IR) -

- First New Drug Application for a GLP-1 receptor agonist to include CV outcomes data -

- Crucial vaccination with Raboral V-RG® continues to help protect wildlife and people against this fatal disease

New National Council on Aging Survey Shows Many Seniors Underestimate the Seriousness of the Flu, Largely Unaware of Vaccine Options1

- LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone -

- Will work together on new digital technology and tools for diabetes -

- Praluent available early next week to U.S. patients -

- Leading influenza vaccine manufacturer to distribute more than 65 million doses to help protect people six months and older against the flu -

Sanofi and Regeneron Engage Academy Award® Winning Documentarian to Capture Behind-the-Scenes Look at Life with an Invisible Condition

- ELIXA is the first event-driven cardiovascular outcomes study to provide data for a GLP-1 receptor agonist -

- Includes study in patients who were inadequate responders to, or intolerant of, TNF-alpha inhibitors -

- Phase 3 Clinical Trial in Uncontrolled Persistent Asthma Underway -

Despite CDC recommendations, fewer than 30% of teens received the second vaccination to help protect against meningococcal meningitis; new survey reveals potential reasons why

U.S. Patent and Trademark Office Honors Sanofi for its Anti-Malarial Treatment

Approval allows children to receive a combination of two recommended vaccinations

- Results support resubmission of U.S. New Drug Application in Q3 2015 -

Allergy sufferers are encouraged to share the #HappySmells they experience this season

- Robust and consistent LDL-C lowering demonstrated with Praluent™ in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date -

View the Interactive Maps on www.CholesterolCounts.com for a Snapshot of Cholesterol Awareness Across the U.S.

America's Leading National Consumer Research Survey Ranks Gold Bond Products #1 in "U.S. Body Comfort and Relief" and "U.S. Skincare" Categories

Further education about hypoglycemia and routinely monitoring blood glucose levels is needed

- Primary efficacy endpoints met in two trials of alirocumab administered every four weeks -

Awards will provide funding for innovative diabetes researchers

Employees and contractors celebrate two decades of delivering essential items to Monroe County Head Start children and families

New program will spotlight America’s high cholesterol numbers

- The first and only four-strain influenza vaccine option administered intradermally -

Sanofi Commitment to Research and Develop TB Treatments, Diagnostics and Vaccines Spans More than 50 Years

- All six trials met primary efficacy endpoint -

IcyHot SmartRelief System Provides Physical Therapist-Trusted TENS Technology for Persistent, Chronic Back Pain Relief That Starts at the Touch of a Button

- Dupilumab Demonstrated Improvement in Lung Function, Reductions of Severe Exacerbations -

- Includes New Data Showing Fluzone High-Dose Vaccine More Efficacious Than Standard-Dose Fluzone Vaccine -

The two companies will develop a product jointly through phase II

More Than $83,000 Raised Benefiting Boys & Girls Clubs of NEPA, Employment Opportunity and Training Center, and Marley’s Mission

- Up to $200 Million Collaboration to Support Pioneering Science and New Treatments -

Approval aligns with Centers for Disease Control and Prevention's recommendations for meningococcal vaccination

- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial -

- Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older -

- Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older -

Generics Division of Sanofi, Winthrop US, to Market the Drug

- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor -

- Largest U.S. influenza vaccine supplier, providing broad product portfolio, will distribute at least 65 million doses to help protect people across multiple age groups against the virus this season -

- Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine –

- Toujeo dossier already accepted by EMA -

-- Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions --

- Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events of up to 31% at night-time compared with Lantus® -

During the 1-year program, patients showed statistically significant reductions in blood glucose levels, increased belief in their ability to self-manage their diabetes and improved perceptions of support, while the community showed statistically significant increases in diabetes awareness

- Initial focus on insulin-device combinations and care management services -

For Millions Of Sufferers, Heartburn Can Be Spelled Many Different Ways But Relief Can Always Be Spelled R-O-L-A-I-D-S

Results indicate vaccine generates an immune response against key toxins in volunteers and establish dosing for Phase III

- What's Your AQ? Answers Common Anaphylaxis Questions During National Asthma and Allergy Awareness Month -

$100,000 prize and access to additional expertise awarded to support "big data" genetic analysis to provide new clues to the higher incidence of ALS in veterans

Olympic Medalist swimmer and mother, Dara Torres, and the National Association of School Nurses launch multi-city health initiative as part of Voices of Meningitis™

Nasal allergy sufferers now have the most effective player on their team to relieve even the toughest nasal allergy symptoms

New investigational PCSK9 inhibitor shown to significantly reduce LDL-C among Japanese patients

Approval reinforces the safety profile of Adacel as an active booster immunization for the prevention of tetanus, diphtheria, and pertussis

Companies to Host Investor Conference Call on Alirocumab on March 31 at 9 AM EDT

Fewer Moms are Aware of Prescription Treatments for Head Lice Compared to OTC Yet Those Who Used an Rx Report Greater Satisfaction

First and only medicine in its class approved for over-the-counter use that provides 24 hour relief of the full range of nasal allergy symptoms including nasal congestion